- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01136408
A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Aki-gun, Hiroshima, Japonsko
- 1160.49.024 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japonsko
- 1160.49.025 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japonsko
- 1160.49.026 Boehringer Ingelheim Investigational Site
-
Himeji, Hyogo, Japonsko
- 1160.49.021 Boehringer Ingelheim Investigational Site
-
Iizuka,Fukuoka, Japonsko
- 1160.49.027 Boehringer Ingelheim Investigational Site
-
Kyoto, Kyoto, Japonsko
- 1160.49.013 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japonsko
- 1160.49.011 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japonsko
- 1160.49.012 Boehringer Ingelheim Investigational Site
-
Naka-gun, Ibaragi, Japonsko
- 1160.49.004 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japonsko
- 1160.49.022 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japonsko
- 1160.49.023 Boehringer Ingelheim Investigational Site
-
Oota, Tokyo, Japonsko
- 1160.49.006 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japonsko
- 1160.49.016 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japonsko
- 1160.49.017 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japonsko
- 1160.49.018 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japonsko
- 1160.49.019 Boehringer Ingelheim Investigational Site
-
Sakai, Osaka, Japonsko
- 1160.49.020 Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japonsko
- 1160.49.001 Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japonsko
- 1160.49.028 Boehringer Ingelheim Investigational Site
-
Sendai, Miyagi, Japonsko
- 1160.49.002 Boehringer Ingelheim Investigational Site
-
Shinjuku, Tokyo, Japonsko
- 1160.49.005 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japonsko
- 1160.49.014 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japonsko
- 1160.49.015 Boehringer Ingelheim Investigational Site
-
Tokorozawa, Saitama, Japonsko
- 1160.49.007 Boehringer Ingelheim Investigational Site
-
Toyama, Toyama, Japonsko
- 1160.49.009 Boehringer Ingelheim Investigational Site
-
Tsuchiura, Ibaragi, Japonsko
- 1160.49.003 Boehringer Ingelheim Investigational Site
-
Ueda, Nagano, Japonsko
- 1160.49.029 Nagano National Hospital
-
Yokohama, Kanagawa, Japonsko
- 1160.49.008 Boehringer Ingelheim Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion criteria Inclusion criteria
- Patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
Patients who had additional risk factor for thromboembolism; one or more of the following conditions/events:
- Hypertension
- Diabetes mellitus
- Left-side heart failure
- A previous ischemic stroke or transient ischemic attack
- Age 75 years or older
- A history of coronary artery diseases
Exclusion criteria Exclusion criteria
- Patients diagnosed as having a valvular heart disease by echocardiography, or patients who had a history of prosthetic valve replacement or valve surgery
- Patients who were to receive electric defibrillation or pharmacological defibrillation during the study period
- Patients who developed stroke or transient ischemic attack within 30 days before the date of informed consent
- Patients who developed myocardial infarction or were admitted to hospital due to acute coronary syndrome or for percutaneous transluminal coronary angioplasty within 3 months before the date of informed consent or patients underwent coronary stenting within 6 months before the date of informed consent
- Patients with atrial myxoma or left ventricular thrombosis
- Patients with contraindication to anticoagulant therapies
- Patients scheduled for major surgery or invasive procedure
- Patients having major bleeding from non-gastrointestinal organs within 6 months before the date of informed consent
- Patients with uncontrolled hypertension
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Dabigatran etexilate 220 mg daily
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
|
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Experimentální: Dabigatran etexilate 300 mg daily
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Aktivní komparátor: Warfarin
Dose-adjusted warfarin based on target INR values
|
Warfarin s upravenou dávkou na základě cílových hodnot INR
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Frequency (Occurrence Rates) of Major Bleeding Event
Časové okno: upto 15 weeks
|
The percentage of patients with major bleeding event. Major bleeding was defined as any bleed fulfilling one of the following conditions:
|
upto 15 weeks
|
Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event
Časové okno: upto 15 weeks
|
The percentage of patients with clinically relevant bleeding event. Any bleed that did not qualify as a major bleed was defined as a minor bleed; minor bleed which fulfilled one of the criteria below was defined as a clinically relevant bleeding event:
|
upto 15 weeks
|
Frequency (Occurrence Rates) of Nuisance Bleeding Event
Časové okno: Upto 15 weeks
|
The percentage of patients with nuisance bleeding event Any bleed that did not qualify as a major bleed was defined as a minor bleed; all minor bleeding events not fulfilling one of the criteria below was defined as a nuisance bleeding event:
|
Upto 15 weeks
|
Incidence and Severity of Adverse Events
Časové okno: Upto 15 weeks
|
Intensity of event is categorised as mild, moderate and severe.
|
Upto 15 weeks
|
Discontinuation of the Study Drug Due to Adverse Events
Časové okno: Upto 15 weeks
|
Discontinuation of the study drug due to adverse events.
|
Upto 15 weeks
|
Changes in Laboratory Test Values
Časové okno: 12 weeks
|
The number of patients with ALT, AST, alkaline phosphatase, or bilirubin exceeded the upper limit of normal (ULN) range
|
12 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Frequency (Occurrence Rates) of a Composite Clinical Endpoint.
Časové okno: Upto 15 weeks
|
Percentage of patients with the composite clinical endpoint (ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)
Časové okno: Upto 15 weeks
|
The percentage of patients with ischemic or haemorrhagic stroke (fatal or non-fatal)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Transient Ischemic Attack
Časové okno: Upto 15 weeks
|
The percentage of patients with transient ischemic attack
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Systemic Embolism
Časové okno: Upto 15 weeks
|
The percentage of patients with systemic embolism
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)
Časové okno: Upto 15 weeks
|
The percentage of patients with myocardial infarction (fatal or non-fatal)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events
Časové okno: Upto 15 weeks
|
The percentage of patients with other major adverse cardiac events
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Death
Časové okno: Upto 15 weeks
|
The percentage of patients with death
|
Upto 15 weeks
|
Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)
Časové okno: Week 0,1,4 and 12
|
The blood coagulation parameter aPTT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough ECT (Ecarin Clotting Time)
Časové okno: Week 0,1,4 and 12
|
The blood coagulation parameter ECT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough INR (International Normalised Ratio)
Časové okno: Week 0,1,4 and 12
|
The blood coagulation parameter INR was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough 11-dehydrothromboxane B2
Časové okno: Week 0 and 12
|
Analysis based on concomitant use of aspirin compared to no aspirin users.
11-dehydrothromboxane B2 is measured in urine of patients.
|
Week 0 and 12
|
Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration
Časové okno: Week 1,4 and 12
|
Week 1,4 and 12
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 1160.49
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Fibrilace síní
Klinické studie na Dabigatran etexilate
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Centre Hospitalier Universitaire de Saint EtienneGroupe de Recherche sur la ThromboseDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončenoKrvácení | Fibrilace síníSpojené státy
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Doasense GmbHAktivní, ne náborAntikoagulační terapieNěmecko
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimHealth ResearchTx, LLC (HRTX); inVentiv Health Clinical (iVH); United States...Dokončeno